Resumo

Pleuropulmonary Fibrosis Associated with the Chronic Intake of Ergotamine. Rev. am. med. respir. [online]. 2020, vol.20, n.2, pp.181-184. ISSN 1852-236X.

Ergotamine is used as a treatment of various diseases. Its chronic use may cause pleuropulmonary, retroperitoneal or pericardial fibrosis. Although pleuropulmonary fibrosis is an uncommon adverse effect, it may be serious and irreversible, thus the early suspension of the drug is the specific treatment. We report three cases of pleuropulmonary fibrosis associated with the chronic intake of ergotamine. In all the cases, the prolonged time of use of this drug and the lack of exposure to other possible drugs or agents acceptable to generate this pleuropulmonary alteration were the main diagnostic indicators, since there aren’t any specific supplementary studies.

Palavras-chave : Ergotamine; Ergotamine/Adverse effects; Pulmonary fibrosis.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )